AQUA PHARMACEUTICALS, LLC – Trademark Portfolio
Entity Type: 16
AQUA PHARMACEUTICALS, LLC holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 18 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include CORDRAN, XOLEGEL, ACTICLATE, FLUOROPLEX, and AQUA PHARMACEUTICALS. The owner is based in WEST CHESTER, PA.
158 WEST GAY STREET, SUITE 310
WEST CHESTER, PA 19380
Showing of trademarks Trademarks
Trademark Classifications
AQUA PHARMACEUTICALS, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does AQUA PHARMACEUTICALS, LLC have?
AQUA PHARMACEUTICALS, LLC has 19 U.S. trademarks filed with the USPTO. Of these, 5 registered, 8 abandoned, 6 cancelled.
What trademark classes does AQUA PHARMACEUTICALS, LLC file in?
AQUA PHARMACEUTICALS, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are AQUA PHARMACEUTICALS, LLC's most well-known trademarks?
AQUA PHARMACEUTICALS, LLC's registered trademark portfolio includes well-known marks such as CORDRAN, XOLEGEL, ACTICLATE, FLUOROPLEX, and AQUA PHARMACEUTICALS. These are among 5 currently registered trademarks in the portfolio.
What is AQUA PHARMACEUTICALS, LLC's trademark registration success rate?
AQUA PHARMACEUTICALS, LLC has a 26% trademark registration rate, with 5 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.